Kidney international
July 24, 2026 · via Europe PMC
Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes.
Xu Y, Maas CCHM, Huang T, Wang T, Créon A, Sjölander A, Fu EL, Carrero JJ.
AI summary — for doctors, generated from the abstract only
A large real-world study found that GLP-1 receptor agonists provided meaningfully greater kidney protection in patients with type 2 diabetes who were already at higher risk of kidney disease progression, while patients at low baseline risk saw little to no benefit, supporting more personalized prescribing based on kidney risk.
What was studied
Using a target trial emulation framework with over 28,000 adults with type 2 diabetes in Stockholm (2008-2021), researchers compared kidney outcomes between new users of GLP-1 receptor agonists (GLP-1RA, n=11,772) and DPP-4 inhibitors (DPP-4i, n=16,775), using both risk modeling (Kidney Failure Risk Equation) and machine learning (causal survival forests) to identify which patient subgroups derived the most kidney benefit.
Key findings
- Overall, GLP-1RA initiation was associated with a lower 5-year risk of the composite kidney outcome compared with DPP-4i (risk difference -0.72%, 95% CI -1.53 to 0.13; hazard ratio 0.84, 95% CI 0.72-0.97).
- Risk modeling showed pronounced heterogeneity: patients in the highest Kidney Failure Risk Equation quartile had a substantial absolute risk reduction with GLP-1RA (-2.76%, 95% CI -5.60 to -0.08; HR 0.70, 95% CI 0.56-0.86), while those in the lowest-risk quartile showed no benefit.
- A separate machine learning (causal survival forest) approach similarly found a significant benefit in the highest-risk quartile (HR 0.79, 95% CI 0.65-0.94) but no significant benefit in the lowest-risk quartile (HR 1.06, 95% CI 0.54-1.74).
- Key predictors of greater treatment benefit included lower baseline eGFR, faster preceding eGFR decline, higher albuminuria, higher HbA1c, and greater prior healthcare utilization.
Clinical relevance
The findings suggest that GLP-1 receptor agonists provide the greatest kidney protection benefit in patients with type 2 diabetes who already have higher kidney risk (lower eGFR, faster decline, higher albuminuria), supporting more personalized prescribing decisions guided by kidney risk stratification tools like the Kidney Failure Risk Equation, rather than uniform prescribing across all diabetes patients.
Who should care
Limitations
This is an observational, real-world comparison using target trial emulation methodology rather than a randomized controlled trial, so while the approach aims to reduce bias, residual confounding cannot be entirely excluded; some confidence intervals (e.g., the overall risk difference) were wide and crossed the null.
GLP-1 receptor agonists showed substantially greater kidney protection benefit in type 2 diabetes patients with higher baseline kidney risk, with little to no benefit in lower-risk patients, supporting personalized, risk-stratified prescribing of these drugs for kidney protection.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Introduction
On average, glucagon-like peptide-1 receptor agonists (GLP-1RA) lower the risk of kidney outcomes in type 2 diabetes, but individual responses may differ. Here, we aimed to identify patient subgroups more likely to derive kidney benefit from GLP-1RA therapy.
Methods
Using a target trial emulation framework, we conducted a new-user, active comparator cohort study that included over 28,000 individuals with type 2 diabetes initiating either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i) in Stockholm (2008-2021). Heterogeneous treatment effects on a composite kidney outcome were estimated using complementary approaches: risk modelling with the kidney failure risk equation (KFRE) and effect modelling with causal survival forests. For interpretability, Shapley Additive Explanations identified clinical features driving benefit.
Results
We included 11,772 GLP-1RA and 16,775 DPP-4i initiators. Compared with DPP-4i, GLP-1RA initiation was associated with a lower five-year risk of kidney outcomes (risk difference -0.72% [95% confidence interval -1.53 to 0.13]; hazard ratio [HR] 0.84 [0.72-0.97]). Risk modelling revealed pronounced heterogeneity: patients in the highest KFRE-risk quarter experienced a substantial absolute risk reduction (-2.76% [-5.60 to -0.08]; HR 0.70 [0.56-0.86]), whereas those in the lowest quarter showed no benefit. Effect modelling similarly contrasted quarters 4 vs. 1 (HR 0.79 [0.65-0.94] vs. 1.06 [0.54-1.74]). Key predictors of treatment benefit included lower baseline estimated glomerular filtration rate (eGFR), faster preceding eGFR decline, higher albuminuria, higher glycated hemoglobin, and greater healthcare utilization prior to treatment start.
Conclusions
GLP-1RA therapy confers heterogeneous kidney benefits in type 2 diabetes, with certain high-risk subgroups experiencing the largest risk reduction. Such findings support personalized GLP-1RA prescribing guided by kidney function/damage, trajectories of eGFR decline, and KFRE risk stratification.
DOI
10.1016/j.kint.2026.06.041
PMID
42498061
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed